Zhu Nanbo, Faucon Anne-Laure, Kuja-Halkola Ralf, Landén Mikael, Xu Hong, Carrero Juan Jesús, Evans Marie, Chang Zheng
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Epidemiology, Centre for Research in Epidemiology and Population Health, INSERM U1018, Paris-Saclay University, Villejuif, France.
Am J Kidney Dis. 2025 May;85(5):577-588.e1. doi: 10.1053/j.ajkd.2024.12.004. Epub 2025 Feb 25.
RATIONALE & OBJECTIVE: Patients with chronic kidney disease (CKD) often face mental health problems, but the burden of severe mental illness (SMI) in this population is unclear. We estimated the prevalence of SMIs among people with CKD and their associations with health outcomes.
Nationwide cross-sectional and cohort study.
SETTING & PARTICIPANTS: Using the Swedish Renal Registry, we identified 32,943 patients with incident CKD G3b-5 or kidney replacement therapy (KRT) between 2008 and 2020 for estimation of the prevalence of SMIs. Data about the 30,103 patients not receiving KRT were used to examine associations between SMIs and subsequent health outcomes.
Occurrence of SMIs (ie, schizophrenia, bipolar disorder, and major depressive disorder) before the date of first registration into the registry (index date), using diagnoses from inpatient or specialist outpatient care.
30% decline in eGFR, initiation of KRT, and all-cause mortality.
Prevalence of SMIs was estimated in patients with CKD and compared with the general population using standardization with ratios adjusted for age, sex, and calendar year. Associations between SMIs and health outcomes were examined using Cox proportional hazards models.
The overall prevalence of SMI was 7.3% in patients with CKD, which was 56% higher than the general population. The prevalences for schizophrenia, bipolar disorder, and major depressive disorder were 0.5%, 2.1%, and 5.6%, respectively. All 3 SMIs were associated with a higher mortality rate. Schizophrenia was not associated with 30% decline in eGFR (HR, 0.92 [95% CI, 0.65-1.29]), but it was associated with a lower rate of initiating KRT (HR, 0.56 [95% CI, 0.39-0.80]). Bipolar disorder was associated with a higher rate of 30% decline in eGFR (HR, 1.47 [95% CI, 1.29-1.67]) but a lower rate of initiating KRT (HR, 0.79 [95% CI, 0.67-0.94]). Major depressive disorder was not associated with 30% decline in eGFR or initiation of KRT.
Lack of primary care data and exclusion of individuals with CKD G1-3a.
Patients with CKD had a higher prevalence of SMI compared with the general population. In patients with CKD, each SMI was associated with higher mortality, and bipolar disorder was associated with a faster eGFR decline. Patients with CKD and pre-existing schizophrenia or bipolar disorder experienced a lower rate of initiating KRT.
PLAIN-LANGUAGE SUMMARY: Patients with chronic kidney disease (CKD) frequently experience mental health problems, yet the prevalence and impact of severe mental illness (SMI) in this population remain uncertain. This Swedish nationwide study revealed that the prevalence of any SMI was 7.3% among patients with CKD (0.5% for schizophrenia, 2.1% for bipolar disorder, and 5.6% for major depressive disorder), representing a 56% higher prevalence than experienced by the Swedish general population. All 3 SMIs were associated with a higher mortality rate in patients with CKD, and bipolar disorder was also associated with a faster eGFR decline. Moreover, patients with CKD and schizophrenia or bipolar disorder exhibited a lower rate of initiating kidney replacement therapy. These findings highlight the need for improved recognition and management of SMI among people with kidney disease.
慢性肾脏病(CKD)患者常面临心理健康问题,但该人群中严重精神疾病(SMI)的负担尚不清楚。我们估计了CKD患者中SMI的患病率及其与健康结局的关联。
全国性横断面和队列研究。
利用瑞典肾脏登记处,我们确定了2008年至2020年间32943例新发CKD G3b - 5期患者或接受肾脏替代治疗(KRT)的患者,以估计SMI的患病率。关于30103例未接受KRT患者的数据用于检验SMI与后续健康结局之间的关联。
根据住院或专科门诊护理诊断,在首次登记入登记处(索引日期)之前发生的SMI(即精神分裂症、双相情感障碍和重度抑郁症)。
估算肾小球滤过率(eGFR)下降30%、开始KRT以及全因死亡率。
估计CKD患者中SMI的患病率,并通过对年龄、性别和日历年进行调整的比率标准化,与普通人群进行比较。使用Cox比例风险模型检验SMI与健康结局之间的关联。
CKD患者中SMI的总体患病率为7.3%,比普通人群高56%。精神分裂症、双相情感障碍和重度抑郁症的患病率分别为0.5%、2.1%和5.6%。所有这三种SMI均与较高的死亡率相关。精神分裂症与eGFR下降不相关(风险比[HR],0.92[95%置信区间(CI),0.65 - 1.29]),但与开始KRT的比率较低相关(HR,0.56[95%CI,0.39 - 0.80])。双相情感障碍与eGFR下降30%的比率较高相关(HR,1.47[95%CI,1.29 - 1.67]),但开始KRT的比率较低(HR,0.79[95%CI,0.67 - 0.94])。重度抑郁症与eGFR下降30%或开始KRT均不相关。
缺乏初级保健数据且排除了CKD G1 - 3a期患者。
与普通人群相比,CKD患者中SMI的患病率更高。在CKD患者中,每种SMI均与较高的死亡率相关,双相情感障碍与eGFR下降更快相关。患有CKD且已有精神分裂症或双相情感障碍的患者开始KRT的比率较低。
慢性肾脏病(CKD)患者经常出现心理健康问题,但该人群中严重精神疾病(SMI)的患病率和影响仍不确定。这项瑞典全国性研究表明,CKD患者中任何SMI的患病率为7.3%(精神分裂症为0.5%,双相情感障碍为2.1%,重度抑郁症为5.6%),比瑞典普通人群的患病率高56%。所有这三种SMI均与CKD患者较高的死亡率相关,双相情感障碍还与eGFR下降更快相关。此外,患有CKD和精神分裂症或双相情感障碍的患者开始肾脏替代治疗的比率较低。这些发现凸显了改善对肾病患者中SMI的识别和管理的必要性。